Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Quality of life · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Human activated protein C vs heparin Overall mortality · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 132 participants | Ungraded |
Recombinant human soluble thrombomodulin vs heparin Adverse events · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | RR 0.88 [0.35, 2.2] | 1 study · 231 participants | Very low |
Recombinant human soluble thrombomodulin vs heparin Bleeding · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 234 participants | Very low |
Recombinant human soluble thrombomodulin vs heparin Resolution of respiratory failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human soluble thrombomodulin vs heparin Renal failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human soluble thrombomodulin vs heparin Shock · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Tranexamic acid vs placebo Overall mortality · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Ungraded |
Tranexamic acid vs placebo Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Ungraded |
Tranexamic acid vs placebo Adverse events · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Very low |
Tranexamic acid vs placebo Bleeding · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Very low |
Tranexamic acid vs placebo Resolution of respiratory failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Ungraded |
Human activated protein C vs heparin Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | RR 0.51 [0.27, 0.97] | 1 study · 104 participants | Very low |
Tranexamic acid vs placebo Renal failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Ungraded |
Tranexamic acid vs placebo Shock · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 12 participants | Ungraded |
Dermatan vs heparin Overall mortality · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 10 participants | Ungraded |
Dermatan vs heparin Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Dermatan vs heparin Adverse events · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Dermatan vs heparin Bleeding · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | RR 0.5 [0.06, 3.91] | 1 study · 10 participants | Very low |
Dermatan vs heparin Resolution of respiratory failure ‐ not measured · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Dermatan vs heparin Renal failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Dermatan vs heparin Shock · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Human activated protein C vs heparin Adverse events · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | RR 0.53 [0.05, 5.66] | 1 study · 107 participants | Very low |
Human activated protein C vs heparin Bleeding · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | RR 0.06 [0, 1.09] | 1 study · 132 participants | Very low |
Human activated protein C vs heparin Resolution of respiratory failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Human activated protein C vs heparin Renal failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Human activated protein C vs heparin Shock · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human soluble thrombomodulin vs heparin Overall mortality · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | 1 study · 234 participants | Ungraded |
Recombinant human soluble thrombomodulin vs heparin Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | RR 0.85 [0.54, 1.36] | 1 study · 227 participants | Very low |
Summary of findings: Ursodeoxycholic acid vs placebo or no treatment Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with a variety of malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.6 [0.4, 0.88] | 4 studies · 612 participants | Low |
Summary of findings: Heparin vs no treatment Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.28 [0.06, 1.32] | 1 study · 161 participants | Low |
Summary of findings: Heparin vs no treatment Quality of life · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs no treatment Frequency of adverse events ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 6.91 [0.36, 131.75] | 1 study · 161 participants | Very low |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.27 [0.06, 1.18] | 1 study · 45 participants | Very low |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Overall survival · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Mortality attributable to hepatic veno‐occlusive disease · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Quality of life · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.74 [0.27, 2] | 1 study · 61 participants | Very low |
Summary of findings: Defibrotide vs no treatment Incidence of hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.62 [0.38, 1.02] | 1 study · 360 participants | Low |
Summary of findings: Ursodeoxycholic acid vs placebo or no treatment Overall survival ( · People undergoing stem cell transplant with a variety of malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | HR 0.83 [0.59, 1.18] | 3 studies · 474 participants | Low |
Summary of findings: Defibrotide vs no treatment Overall survival ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | HR 1.04 [0.54, 2.02] | 1 study · 356 participants | Low |
Summary of findings: Defibrotide vs no treatment All‐cause mortality at 100 days post‐transplant ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 1.05 [0.56, 1.97] | 1 study · 360 participants | Low |
Summary of findings: Defibrotide vs no treatment Mortality attributable to hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.4 [0.13, 1.24] | 1 study · 360 participants | Low |
Summary of findings: Defibrotide vs no treatment Quality of life · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Defibrotide vs no treatment Frequency of adverse events ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 18.79 [1.1, 320.45] | 1 study · 360 participants | Very low |
Summary of findings: Glutamine vs placebo Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | 1 study · 34 participants | Very low |
Summary of findings: Glutamine vs placebo Overall survival · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Glutamine vs placebo All‐cause mortality at 100 days post‐transplant ( · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.3 [0.01, 6.84] | 1 study · 34 participants | Very low |
Summary of findings: Glutamine vs placebo Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | 1 study · 34 participants | Very low |